Wells Fargo
FATE icon

Wells Fargo’s Fate Therapeutics FATE Stock Holding History

Wells Fargo’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121K Sell
100,975
-71,308
-41% -$86.8K ﹤0.01% 4996
2025
Q4 		$169K Buy
172,283
+38,444
+29% +$46.2K ﹤0.01% 5159
2025
Q3 		$169K Buy
133,839
+11,647
+10% +$12.6K ﹤0.01% 5026
2025
Q2 		$137K Buy
122,192
+19,254
+19% +$22.4K ﹤0.01% 4995
2025
Q1 		$81.3K Buy
102,938
+10,543
+11% +$12.9K ﹤0.01% 5207
2024
Q4 		$152K Buy
92,395
+33,284
+56% +$83.9K ﹤0.01% 4952
2024
Q3 		$207K Buy
59,111
+1,859
+3% +$7.23K ﹤0.01% 4555
2024
Q2 		$188K Buy
57,252
+16,239
+40% +$71.1K ﹤0.01% 4553
2024
Q1 		$301K Buy
41,013
+2,673
+7% +$16.5K ﹤0.01% 4219
2023
Q4 		$143K Buy
38,340
+4,035
+12% +$9.53K ﹤0.01% 4676
2023
Q3 		$72.7K Sell
34,305
-177,819
-84% -$589K ﹤0.01% 4959
2023
Q2 		$1.01M Sell
212,124
-56,803
-21% -$313K ﹤0.01% 3470
2023
Q1 		$1.53M Buy
268,927
+218,236
+431% +$1.32M ﹤0.01% 3082
2022
Q4 		$511K Buy
50,691
+4,071
+9% +$76.5K ﹤0.01% 3620
2022
Q3 		$1.04M Buy
46,620
+1,011
+2% +$29.2K ﹤0.01% 3213
2022
Q2 		$1.13M Sell
45,609
-96,789
-68% -$2.67M ﹤0.01% 3216
2022
Q1 		$5.52M Sell
142,398
-39,747
-22% -$1.54M ﹤0.01% 2375
2021
Q4 		$10.7M Sell
182,145
-198,946
-52% -$11.3M ﹤0.01% 1825
2021
Q3 		$22.6M Buy
381,091
+54,322
+17% +$4.26M 0.01% 1563
2021
Q2 		$28.4M Buy
326,769
+118,761
+57% +$9.57M 0.01% 1422
2021
Q1 		$17.1M Sell
208,008
-19,723
-9% -$1.89M ﹤0.01% 1788
2020
Q4 		$20.7M Sell
227,731
-20,315
-8% -$1.26M 0.01% 1531
2020
Q3 		$9.91M Sell
248,046
-95,754
-28% -$3.34M ﹤0.01% 1899
2020
Q2 		$11.8M Sell
343,800
-79,851
-19% -$2.38M ﹤0.01% 1729
2020
Q1 		$9.41M Sell
423,651
-75,309
-15% -$1.9M ﹤0.01% 1717
2019
Q4 		$9.77M Buy
498,960
+45,845
+10% +$728K ﹤0.01% 1982
2019
Q3 		$7.04M Sell
453,115
-25,900
-5% -$496K ﹤0.01% 2233
2019
Q2 		$9.72M Buy
479,015
+338,130
+240% +$6.09M ﹤0.01% 1993
2019
Q1 		$2.48M Sell
140,885
-21,667
-13% -$342K ﹤0.01% 3174
2018
Q4 		$2.08M Sell
162,552
-27,011
-14% -$377K ﹤0.01% 3236
2018
Q3 		$3.09M Buy
189,563
+71,940
+61% +$851K ﹤0.01% 3044
2018
Q2 		$1.33M Buy
117,623
+12,976
+12% +$143K ﹤0.01% 3780
2018
Q1 		$1.02M Sell
104,647
-223,376
-68% -$2.14M ﹤0.01% 3903
2017
Q4 		$2M Buy
328,023
+84,269
+35% +$376K ﹤0.01% 3368
2017
Q3 		$965K Sell
243,754
-9,309
-4% -$31.7K ﹤0.01% 3882
2017
Q2 		$820K Sell
253,063
-28,048
-10% -$107K ﹤0.01% 3879
2017
Q1 		$1.28M Buy
281,111
+253,732
+927% +$928K ﹤0.01% 3561
2016
Q4 		$69K Buy
27,379
+712
+3% +$1.91K ﹤0.01% 5290
2016
Q3 		$83K Buy
26,667
+25,667
+2,567% +$62.3K ﹤0.01% 5022
2016
Q2 		$2K Hold
1,000
– – ﹤0.01% 5943
2016
Q1 		$2K Hold
1,000
– – ﹤0.01% 6026
2015
Q4 		$3K Hold
1,000
– – ﹤0.01% 5958
2015
Q3 		$5K Sell
1,000
-1,000
-50% -$6.83K ﹤0.01% 5848
2015
Q2 		$13K Hold
2,000
– – ﹤0.01% 5726
2015
Q1 		$10K Hold
2,000
– – ﹤0.01% 5628
2014
Q4 		$10K Buy
+2,000
New +$8.83K ﹤0.01% 5623
2014
Q2 		– Sell
-9,949
Closed -$97K – 6154
2014
Q1 		$97K Buy
+9,949
New +$76.8K ﹤0.01% 4663

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo's FATE Position: Q1 2026 in Review

Wells Fargo reduced its Fate Therapeutics (FATE) stake by 41% in Q1 2026, selling an estimated $86.8K and leaving 100,975 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #4996.

Wells Fargo first reported a position in FATE in Q1 2014 and has held it in 47 quarters since. The position peaked at $28.4M in Q2 2021. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Wells Fargo held 100,975 shares of Fate Therapeutics worth $121K as of Q1 2026.
  • Wells Fargo sold 71,308 Fate Therapeutics shares in Q1 2026, an estimated $86.8K.
  • Fate Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4996 holding.
  • Wells Fargo first reported a position in Fate Therapeutics in Q1 2014 and has held it in 47 quarters since.
  • Wells Fargo's Fate Therapeutics position peaked at $28.4M in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.